The standard treatment of human visceral leishmaniasis involves the use of pentavalent antimony (Sb V ). Its mechanism of action is unknown because of the limited information available about intracellular antimony metabolism and about the genes that regulate these processes. Herein, flow injection-inductively coupled plasma mass spectrometry (ICP-MS), flow injection hydride generation ICP-MS, and ion chromatography ICP-MS were used to measure antimony accumulation and intracellular metabolism in the human protozoan parasite Leishmania donovani. V reduction has yet to be identified, and it may or may not be enzymatic. This is the first description of intracellular Sb V reducing activity in Leishmania as well as in any prokaryotic or eukaryotic cell.
inhibited the toxicity of Sb III but not of As III . Both Sb V and Sb III were toxic to wild-type amastigotes. However, as observed in promastigotes, in mutant amastigotes Sb V inhibits Sb III but not As III activity. Anion exchange chromatography showed that intracellular antimony metabolism occurred in both promastigotes and amastigotes. These data demonstrate that the interaction between the two antimony oxidation states occurs intracellularly, within the parasite. The results also indicate that Sb V anti-leishmanial activity is dependent on its reduction to Sb III . The mechanism of this novel intracellular Sb V reduction has yet to be identified, and it may or may not be enzymatic. This is the first description of intracellular Sb V reducing activity in Leishmania as well as in any prokaryotic or eukaryotic cell.
Leishmania donovani is the major causative agent of visceral leishmaniasis. In nature, the parasite exists either as an extracellular promastigote found in the alimentary tract of sandflies or as an obligatory intracellular amastigote found in phagolysosomes of mammalian macrophages (1) (2) (3) . During the last several years, a number of laboratories have utilized axenic culture of L. donovani amastigotes for the direct evaluation of cell biological and biochemical processes in the amastigote, devoid of the host macrophage (4 -7,8,9,10) . This technique has also been used to investigate the mechanism of drug action and resistance as well as for screening of potential new drugs(11-13). The treatment of choice of human visceral leishmaniasis is the administration of pentavalent antimony (Sb V )-containing drugs such as sodium stibogluconate (Pentostam, Wellcome, Beckenham, UK) or meglumine antimoniate (Glucantime, Rhone-Poulenc, Paris, France). Despite extensive use of these compounds over the last decades, the mechanism of action remains unclear.
It has been hypothesized that Sb V is not toxic to Leishmania, but rather that it is enzymatically reduced, probably by the host macrophage, to Sb III , the form of antimony that is highly Leishmania-toxic (14 -18) . In contrast, it has been shown that Sb V is directly toxic to axenic amastigotes (12, 13, 19) , thus negating the necessity of the macrophage for Sb V reduction. Furthermore, these data imply that either the parasite reduces Sb V to Sb III intracellularly, and thus Sb III is directly toxic to amastigotes, or that both oxidation states of antimony are active against Leishmania amastigotes. The modes of action of the two oxidation states of antimony (Sb  III and Sb   V   ) on Leishmania are, as yet, not fully understood.
Several groups have shown obligatory cross-resistance between Sb V , Sb III , and arsenite (As III ) in Leishmania tarentolae, Leishmania major, Leishmania mexicana, L. donovani and Leishmania infantum (11, 20 -22) . In contrast, it has been suggested that, at least in L. donovani, such cross-resistance does not necessarily occur (12) . Furthermore, it has been demonstrated that, when bound to organic compounds, structural similarities exist between Sb III and Sb V (23) . For example, the trivalent antimony compound potassium antimonyl tartrate has a structure resembling that of the pentavalent antimony compound sodium stibogluconate. Thus it is conceivable that Sb V and Sb III act on a common parasite target molecule. It is also possible that, when given together, these compounds might act additively or synergistically, or might inhibit one another. It is also possible that at least part of the anti-leishmanial activity of As III may not be mediated by a mechanism similar to that of antimony despite the fact that cross-resistance in other Leishmania species has been observed (11, 20 -22) .
To understand the relationships between these compounds and their activity against L. donovani, antimony accumulation and its subsequent intracellular metabolism were investigated using novel antimony speciation methods. 
Culture
Promastigotes were grown in medium 199 at 26°C and supplemented with 10% fetal calf serum. In vitro culture of amastigotes was performed as described by Saar et al. (5) . Transformation of amastigotes to promastigotes was performed by centrifugation of amastigotes (1,200 ϫ g, at room temperature for 10 min), suspension in promastigote medium, and incubation at 26°C. Under these conditions, amastigotes differentiate to promastigotes within 48 h (5).
Dose Response Analyses
Parasite viability was measured using a radiolabeled thymidine incorporation assay as follows: mid-log phase cells (ϳ5 ϫ 10 5 cells/ml) were added in duplicate to 24-well flat-bottomed microtiter plates (2-ml final volume). Drugs were serially added to the cells (either promastigotes or amastigotes), and cells were then incubated for 48 h at either 26°C (promastigotes) or 37°C in 5% CO 2 (amastigotes). Subsequently, 10 l of [ 3 H]thymidine (0.1 mCi/ml) were added to each well and incubated for another 3 h (promastigotes) or 24 h (amastigotes). 1-ml aliquots from each well were centrifuged (1,200 ϫ g at room temperature for 10 min) and added to 5 ml of ice-cold trichloroacetic acid, vortexed, and incubated on ice for about 20 min. Samples were then filtered through a glass microfiber filter (GF/C, Whatman International Ltd., Springfield Mill, UK) and washed once with 10 ml of cold trichloroacetic acid followed by 10 ml of 95% ethanol. Radioactivity was measured using ␤-scintillation counting. Results were expressed as percentage viability.
Determination of Intracellular Antimony
Cell Preparation-L. donovani promastigotes and amastigotes were incubated for 3, 6, Determination of Total Antimony-The content of antimony in each sample was measured using flow injection-inductively coupled plasmamass spectrometry (FI-ICP-MS) 1 at m/z 121 using water as solvent stream (flow rate was 1.5 ml/min, n ϭ 5) under clean room conditions (class 1000). Each sample contained 100-l aliquots of cell extract, which were diluted 1:100 with water (25, 26) . For each measurement, aliquots of 10 l were injected with five repetitions.
Determination of Sb III and Sb V -Intracellular Sb III and Sb V were measured using flow injection-hydride generation-inductively coupled plasma-mass spectrometry (FI-HG-ICP-MS), which has recently been developed (27) . Briefly, Sb III was reduced to antimony hydride (SbH 3 ) using 0.2% sodium tetrahydridoborate in de-ionized water and was directly quantified using mass spectrometry at m/z 121. To avoid Sb V interference with the antimony hydride measurements, the Sb V reduction was suppressed by the addition of 100 mg/liter of fluoride (as KF) to the solvent stream. Subsequently, Sb V was reduced to antimony hydride in 2 steps; pre-reduction using 1.2% KI followed by reduction with 0.2% sodium tetrahydridoborate, both in de-ionized water as solvent stream. The Sb V content in each sample was calculated as the difference between the absorbance determined after the second reduction (Sb III ϩ Sb V ) and first reduction (Sb III ). Nonreducible organic antimony is not detected by this method. For each measurement, aliquots of 100 l were injected with five repetitions.
Anion Exchange Chromatography of Intracellular Antimony-Chromatographic separation of intracellular antimony was done as described by Ulrich et al. (28) . Briefly, cell extracts were diluted 1:100 with distilled water, and 100-l aliquots from each preparation were injected into a laboratory-packed PRP-X100 HPLC column. Sb V and Sb III were eluted from the column using 15 mM nitric acid and were directly injected to ICP-MS (m/z 121) for antimony absorbance. Each sample was filtered and degassed prior to chromatography.
RESULTS
Antimony accumulation in promastigotes and amastigotes of both the wild-type and the mutant L. donovani Ld1S.20 was determined using two different methods. First, total intracellular antimony content was measured with FI-ICP-MS (25, 26) , and the results are summarized under "Total [Sb] i " in Tables 1  and 2 . The second method used to determine the content of antimony hydride (SbH 3 ) was FI-HG-ICP-MS (27, 28) . In this method, Sb V and Sb III in cell extracts were separately reduced to SbH 3 , which then flowed through the plasma to the mass spectrometer, where its concentration was subsequently determined (Tables 1 and 2 With a similar set of experiments using WT and mutant amastigotes, the data in Table 2 1 The abbreviations used are: FI-ICP-MS, flow injection-inductively coupled plasma mass-spectrometry; FI-HG-ICP-MS, flow injectionhydride generation-inductively coupled plasma-mass spectrometry; IC-ICP-MS, ion-chromatography-inductively coupled plasma-massspectrometry; WT, wild type; HPLC, high performance liquid chromatography; LD, lethal dose. In contrast to the above findings, when amastigotes of WT parasites were subjected to the same conditions ( (29) . Hence, it is likely that rapid reduction of Sb V requires intracellular catalytic activity of either an enzymatic or nonenzymatic nature.
To further delineate the nature of the intracellular reduction of Sb V , [Sb III ] i was determined after 3-, 6-, and 12-h incubations of both WT and mutant promastigotes and amastigotes with Sb V alone. As shown in Fig. 1 , WT amastigotes showed a time-dependent reduction of Sb V whereas mutant amastigotes exhibited less than 0.025 of the reducing activity. Promastigotes, both WT and mutants, did not reduce Sb V to any extent. The results in Fig. 1 and Tables 1 and 2 indicate that Sb V reducing activity correlates with the previously documented stage-specific susceptibility of WT amastigotes to pentavalent antimony (12) . However, in amastigotes, the intracellular concentration of Sb V was 5-fold higher than in promastigotes, suggesting that it may also be toxic to amastigotes. (Fig. 2B) .
In contrast, Sb V failed to reverse arsenite (As III ) toxicity to L. donovani even at Sb V concentrations as high as 5 mg/ml (Fig. 2,  A and B (Fig. 3A) . In the presence of 34 g of Sb III /ml (equivalent to the LD 90 ) no inhibition of Sb III toxicity by Sb V was observed. This is in agreement with the previously reported stage-specific susceptibility of L. donovani to Sb V (12) . When the same dose-response analysis was performed using amastigotes of the L. donovani mutant Ld1S.20, Sb V inhibited Sb III toxicity in a fashion similar to that observed in promastigotes. As shown in Fig. 3B , [Sb V ] Ն 200 g/ml reduced mor- (Tables 1  and 2 ). Therefore, to ascertain whether antimony metabolism other than oxidation or reduction occurs intracellularly, cell extracts from the above experiments were subjected to anion exchange chromatography, and fractions eluted from the column were directly subjected to ICP-MS.
When a parasite-free solution containing both sodium stibogluconate and potassium antimonyl tartrate was subjected to HPLC anion exchange chromatography, two distinct peaks (Sb V and Sb III ), were identified. Sb V and Sb III retention times were 100 and 300 s, respectively (not shown). Fig. 4 shows chromatograms of WT and mutant amastigotes and promastigotes incubated with Sb V . As shown, when amastigotes were incubated with Sb V , the Sb III peak was absent in the mutant but not in WT. This correlates with the lack of Sb V reducing activity observed in the mutant amastigotes (Fig. 1) . In both WT and mutant amastigotes, peaks other than free Sb V and Sb III were detected. Differences in peaks A through F were apparent between WT and mutant. These peaks might represent covalent interactions of either Sb V or Sb III with intracellular molecules.
No major differences were observed between WT and mutant promastigotes when incubations were performed with Sb V (Fig.  4, C and D) . Despite the qualitative nature of the chromatographic results, the size of both the promastigote Sb III peaks (WT and mutant) was smaller than in WT amastigotes, further emphasizing the low level of Sb V reducing activity in promastigotes (Fig. 1) .
DISCUSSION
Bacteria and yeast that live in environments contaminated with arsenate (As V ) reduce the element intracellularly to arsenite (As III ) as part of the mechanism that was evolved to evade the toxic effects of this heavy metal (30) . Given that Leishmania spp. are not necessarily exposed to heavy metals in their natural habitats (sandflies and vertebrates), they may not have developed this type of protective mechanism. In fact, by reducing nontoxic Sb V Leishmania, they actually expose themselves to the lethal effects of Sb III . This work aimed to assess the role of Sb V reduction in antimony toxicity to and resistance in L. donovani.
The data presented herein show the following. 1) Intracellular stage-specific Sb V reduction occurs in WT L. donovani 1SR and susceptibility to Sb V correlates with the level of Sb V reducing activity.
2) The Sb V -resistant mutant amastigote of L. donovani Ld1S.20 is deficient in Sb V intracellular reducing activity. 3) Antimony metabolism with stage-specific differences occurs in both promastigotes and amastigotes of WT L. donovani 1SR and 4) stage-specific intracellular competition between Sb III and Sb V , but not As III , occurs in WT L. donovani 1SR. This competition is not related to antimony transport.
The results of the experiments described indicate that Sb V reverses the toxicity of Sb III to L. donovani promastigotes, in both the WT and the mutant L. donovani Ld1S.20. In addition, Sb V and Sb III are toxic in an additive fashion to WT amastigotes. These data support previous findings that described the stage-specific toxicity of Sb V , but not of Sb III , to L. donovani (12) . In contrast, in mutant L. donovani Ld1S.20 amastigotes, a response similar to promastigotes was observed (inhibition).
In both wild-type and mutant promastigotes and amastigotes, no cross-inhibition by Sb V occurs when As III is substituted for Sb III . This suggests that, despite similar activity in other biological systems (30, 31) , in L. donovani, antimony and arsenic may not act via similar mechanisms.
FI-HG-ICP-MS and FI-ICP-MS data show that both antimony oxidation states, either individually or together, enter promastigotes and axenic amastigotes. The specific quantitative results for combined Sb III and Sb V incubation rule out the possibility that competition occurs at the plasma membrane transport level. This is true for both promastigotes and amastigotes of both WT and mutant L. donovani Ld1S.20 parasites.
Because Sb V -Sb III antagonism does not take place at the transport level, the assumption that it transpires intracellularly has been borne out. Cells were pretreated with either 10 g/ml potassium antimonyl tartrate (OE, 3.4 g/ml Sb III ) or 100 g/ml potassium antimonyl tartrate (q, 34 g/ml Sb III ). Viability was determined as described under "Experimental Procedures." B, effect of sodium stibogluconate on the toxicity of potassium antimonyl tartrate and arsenite on amastigotes of the L. donovani mutant Ld1S.20. Amastigotes were pretreated with either 100 g/ml potassium antimonyl tartrate (q, 35 g/ml Sb III ) or 1 g/ml arsenite (f). Viability was determined using reduces negligibly toxic Sb V to highly toxic Sb III . In WT promastigotes, the putative L. donovani stage-specific antimony reducing activity may be expressed at either a low level or may be of very low activity, thus explaining the negligible susceptibility of these promastigotes to Sb V . In the mutant L. donovani Ld1S.20 amastigote Sb V reducing activity is present either in small amounts or may be nonexistent; thus Sb V accumulates intracellularly but is not reduced to Sb III . Consequently mutant amastigotes are less susceptible than WT to Sb V . The data presented in Fig. 1 indicate that in WT amastigotes, stage-specific Sb V reducing activity occurs, whereas in the mutant amastigote, Sb V reduction is less than 0.025 that of WT, thus Sb V accumulates intracellularly but is not reduced to Sb III . Furthermore, the observation that both WT and mutant promastigotes and amastigotes accumulate Sb III to the same level (Tables 1 and 2 ) rules out a possible role for antimonite efflux as the reason for low level of Sb III reduction as well as for Ld1S.20 Sb V resistance. The Sb V reducing activity of L. donovani might resemble that of the arsenate reductase previously described in bacteria and yeast, which catalyzes reduction of As V to As III (30, 32, 33) . It is possible that an L. donovani enzyme that catalyzes Sb V reduction plays a key role in parasite susceptibility to antimony. This possibility is currently being investigated in our laboratory.
In (Table 2) , as seen in both WT and mutant promastigotes as well as in mutant amastigotes. However, the data presented in Fig. 3A show that this does not occur. This might suggest that Sb V is directly toxic to WT amastigotes. If this is the case, it must be assumed that Sb V toxicity is coupled with Sb V reducing activity. Fig. 5 illustrates a model describing antimoniate reduction FIG. 4 . Anion exchange chromatography of antimony in L. donovani. WT and mutants were treated for 6 h with 1 mg of Sb V /ml sodium stibogluconate, and then extracted as described under "Experimental Procedures," subjected to a PRP-X100 HPLC column, and subsequently eluted using 15 mM nitric acid. The eluted samples were injected directly to ICP-MS. A and B, WT and mutant amastigotes, respectively; C and D, WT and mutant promastigotes.
FIG. 5.
A proposed mechanism for antimony metabolism and its neutralization by L. donovani. Both promastigotes and amastigotes accumulate Sb V . Enzymatic reduction of Sb V to Sb III occurs in both life stages, but reducing activity is much higher in amastigotes (current data). Subsequent binding of Sb III to trypanothione and the active efflux of this complex have been previously proposed (20, 34, 35) . and the subsequent neutralization of Sb III by trypanothione. We propose that Sb III accumulates in cells by transport across the plasma membrane and/or by the intracellular reduction of Sb V to Sb III via either an enzymatic or nonenzymatic mechanism. Sb III then complexes with trypanothione, and this complex is then extruded from the parasite via specific transporters, as has been previously proposed (20, 34, 35) . A mutation in a purported stage-specific Sb V reductase would result in resistance of amastigotes to Sb V but not to Sb III . However, any mutation that occurs in enzymes involved in reactions downstream of the site of the proposed Sb V stage-specific reducing activity should result in antimony as well as in arsenite-antimony cross-resistance. This could explain why others have reported Sb V -Sb III -As III cross-resistance in various Leishmania species (11, 20, 22, 36) . Furthermore, the additional role of macrophage-associated antimony reduction in natural infection, as previously suggested (11, 16, 17) , cannot be ruled out.
In promastigotes, the observation that Sb V inhibits Sb III toxicity is surprising. No similar phenomenon has been reported before. The intracellular Sb V antagonism of Sb III toxicity in WT and mutant promastigotes as well as in mutant amastigotes could occur because of a number of possibilities. In solution, gluconic acid dissociates from antimony and is replaced by hydroxyl groups forming hexahydroxyl antimony, whereas tartrate remains conjugated to Sb III . Thus, Sb V antagonism of Sb III is more likely to be a result of noncompetitive inhibition rather than of competitive inhibition (because of structural similarity). Alternatively, an inactive oxide hybrid is formed between potassium antimonyl tartrate and one-half of the sodium stibogluconate molecule. Because Sb V is rapidly reduced to Sb III in amastigotes, such hybrids will probably not form. These possibilities are currently being investigated.
The recently developed antimony anion exchange chromatography method (28) showed that Sb V is not only reduced but also metabolized by L. donovani. Peaks separated from cell extracts after Sb V treatment (Fig. 4) suggest the possibility of covalent interactions of either Sb V or Sb III with intracellular molecules. The bound antimony may not be reduced by BH 4 (27) , thus explaining the differences between total [Sb] i and the reducible intracellular Sb V and Sb III measured in Tables 1 and  2 .
The amount of antimony accumulated in L. donovani promastigotes and amastigotes are 20 and 300 times higher than that reported for L. panamensis (17) . Furthermore, although this New World Leishmania species also exhibits stage-specific susceptibility to Sb V , both developmental stages accumulate it to the same extent. Hence, it is likely that in New and Old World species, Sb V acts via different modes of action. The novel approaches of FI-HG-ICP-MS, FI-ICP-MS, and anion exchange chromatography facilitated the description of intracellular antimony metabolism in L. donovani promastigotes and amastigotes, both WT and mutant. To the best of our knowledge, this is the first description of intracellular Sb V reduction in parasitic protozoa as well as in any intact cell.
